40 Ces Urol 2023; 27(1): 36–40 KAZUISTIKY 2. Brausi M, Oddens J, Sylvester R, et al. Side effects of Bacillus Calmette‑Guerin (BCG) in the treatment of intermediate- and high‑risk Ta, T1 papillary carcinoma of the bladder: results of the EORTC genito‑urinary cancers group randomised phase 3 study comparing one‑third dose with full dose and 1 year with 3 years of maintenance BCG. Eur Urol. 2014; 65: 69. 3. Witjes JA, Palou J, Soloway M, et al. Clinical practice recommendations for the prevention and man‑ agement of intravesical therapy‑associated adverse events. Eur Urol Suppl. 2008; 7: 667. 4. van der Meijden AP, Sylvestrer RJ, Oosterlinck W, et al. Maintenance Bacillus Calmette‑Guerin for Ta T1 bladder tumors is not associated with increased toxicity: results from a European Organisation for Research and Treatment of Cancer Genito‑Urinary Group Phase III Trial. Eur Urol. 2003; 44: 429. 5. Marques M, Vazquez D, Sousa S, et al. Disseminated Bacillus Calmette‑Guérin (BCG) infection with pulmonary and renal involvement: a rare complication of BCG immunotherapy. A case report and narrative review. Pulmonology. 2020; 26(6): 346–352. Hotel Vienna House Andel’s, Stroupežnického 21, Praha 5 Reg i s t race , odborný program a da l š í i n f ormace : www. knou . cz Pořadatel a organizátor 8. ROČNÍK 19.–20. 5. 2023 KOMPLEXNÍ N O V I N K Y V O N K O U R O L O G I I
RkJQdWJsaXNoZXIy NDA4Mjc=